Cincinnati Hematology Experts Showcase Research at National Meet miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.
The gene TRAF6 can block progression from pre-leukemia to full-blown disease, say researchers. But research is still in the early stages and potential therapies and clinical trials may be years away.
Credit: CincyTech
Kurome Therapeutics, a preclinical stage company dedicated to developing novel therapies that target adaptive resistance mechanisms in cancer cells while inhibiting critical disease modifying genes, today announced the closing of a $15 million Series A financing.
The round was co-led by Medicxi and Affinity Asset Advisors with participation from founding investor CincyTech, and other existing seed investors. We are excited to have the support of exceptional investors. This financing allows us to expand our R&D program to substantially de-risk compound selection as we identify our first development candidate in advance of IND filing, said Kurome Chief Executive Officer and Chief Scientific Officer Jan Rosenbaum, PhD.